logo

For the Inventor, By the Inventor

Calgary, Canada

Zenith Epigenetics Corp.


USPTO Granted Patents = 24

% Expired Patents = 62.5



Forward Citations = 233

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal John Frederick Quinn (20 out of 22 patents)

silverMedal Bryan Cordell Duffy (19 out of 19 patents)

bronzeMedal Shuang Liu (18 out of 67 patents)

4.  Gregory Scott Martin (16 out of 18 patents)

5.  Peter Ronald Young (16 out of 20 patents)

6.  Ruifang Wang (15 out of 15 patents)

7.  May Xiaowu Jiang (15 out of 20 patents)

8.  Gregory Steven Wagner (15 out of 18 patents)

9.  He Zhao (8 out of 34 patents)

10.  Michael A Ellis (5 out of 19 patents)

11.  Bruce Francis Molino (5 out of 41 patents)

12.  David John Fairfax (3 out of 10 patents)

13.  Vladimir Khlebnikov (2 out of 6 patents)

14.  Samuel David Brown (2 out of 4 patents)

15.  Olesya Kharenko (2 out of 2 patents)


24 patents:

1. 12145932 - Method of manufacturing a solid form of a BET bromodomain inhibitor (2024-11-19),
2. 11607405 - Combination therapy for the treatment of triple-negative breast cancer (2023-03-21),
3. 11446306 - Bicyclic bromodomain inhibitors (2022-09-20),
4. 11026926 - Substituted bicyclic compounds as bromodomain inhibitors (2021-06-08),
5. 10772892 - Bicyclic bromodomain inhibitors (2020-09-15),
6. 10710992 - Substituted pyridinones as bromodomain inhibitors (2020-07-14),
7. 10500209 - Quinazolinones as bromodomain inhibitors (2019-12-10),
8. 10363257 - Bicyclic bromodomain inhibitors (2019-07-30),
9. 10292968 - Substituted heterocycles as bromodomain inhibitors (2019-05-21),
10. 10231953 - Inhibitors of bromodomains (2019-03-19),
11. 10226451 - Substituted bicyclic compounds as bromodomain inhibitors (2019-03-12),
12. 10179125 - Substituted pyridines as bromodomain inhibitors (2019-01-15),
13. 10166215 - Substituted bicyclic compounds as bromodomain inhibitors (2019-01-01),
14. 10010556 - Bicyclic bromodomain inhibitors (2018-07-03),
15. 9861637 - Heterocyclic compounds as bromodomain inhibitors (2018-01-09),
Company Overview
Zenith Epigenetics Corp. is a biotechnology company based in Calgary, Canada, focused on the development of innovative therapies targeting epigenetic mechanisms. The organization specializes in research aimed at understanding and manipulating gene expression to treat various diseases, particularly cancer. By leveraging advanced scientific techniques, Zenith seeks to pioneer new treatment modalities that can significantly impact patient outcomes, positioning itself at the forefront of epigenetic research and therapeutic development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Zenith Epigenetics Corp. USPTO Patent Assignee Logo
24 Patents

#44 in Calgary

#607 in Canada

#26,686 in the World

Calgary, CA
Calgary, Canada

Zenith Epigenetics Corp.

Forward Citations = 233

26 inventors:

goldMedal John Frederick Quinn (20 out of 22 patents)

silverMedal Bryan Cordell Duffy (19 out of 19 patents)

bronzeMedal Shuang Liu (18 out of 67 patents)

4.  Gregory Scott Martin (16 out of 18 patents)

5.  Peter Ronald Young (16 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zenith Epigenetics Corp.. Retrieved from https://idiyas.com/company/zenith-epigenetics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…